MDWD | MediWound Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	15.81 - 16.85
52 Week Range	8.22 - 24.00
Beta	0.99
Implied Volatility	63.90%
IV Rank	25.18%
Day's Volume	76,994
Average Volume	44,295
Shares Outstanding	10,786,400
Market Cap	180,995,792
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-03-20

Valuation
Profitability
Growth
Health
P/E Ratio	-7.77
Forward P/E Ratio	N/A
EPS	-2.16
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	100
Country	Israel
Website	MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MDWD's peers: CANF, FHTX, ELYM, STRO, DYAI, CRNX, INBX, MRUS, LYEL, KRON, AVTE, KROS, SNDX, MLYS, REPL, OCUL, VCYT, RNA, SWTX, GLUE, NKTX, GBIO, SANA, PLUR

*Chart delayed

Analyzing fundamentals for MDWD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see MDWD Fundamentals page.

Watching at MDWD technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on MDWD Technicals page.